ceftazidime+ciprofloxacin
PreclinicalSmall molecule
ceftazidime+ciprofloxacin is one of 15 small molecule programs targeting Peritonitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Peritonitis
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Doribax
ShionogiApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Chibroxin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Extraneal
VVantive Health LLC
Approved
Itopride,
FForest Laboratories
Phase 3
Avelox
BayerPreclinical
Dalvance
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Peritonitis1 trial
Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
Completed·—·N/A·NCT01785641·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ceftazidime+ciprofloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CChulalongkorn University